[Skip to Content]
[Skip to Content Landing]
November 5, 1973

Tardive Dyskinesia

Author Affiliations

Bonnie Pray Thornton Naples, Fla

JAMA. 1973;226(6):674. doi:10.1001/jama.1973.03230060050026

To the Editor.—  The medical and psychiatric literature regarding the subject of tardive dyskinesia is rapidly accumulating, and cautions are advised regarding the need for the appropriate use of antipsychotic drugs. A recent Food and Drug Administration (FDA) drug bulletin addressed itself to the subject and in keeping with the majority of reports, emphasized the enhanced risk with high dosages and long durations of drug therapy.1 Indeed, the risk may be greater; however, we have recently reported two cases (one being quite severe) with low dosages (J Fla Med Assoc Sept, 1973).They involved chlorpromazine, 50 mg at bedtime, as a hypnotic for approximately 2 1/2 years, and 7.5 mg/ day of fluphenazine for two years, respectively. Recently, Simpson reported three cases of tardive dyskinesia occurring with low dosages.2 One involving trifluperazine, 10 mg daily, for less than one year. This represents only a small number of instances